EUVIMEDSkopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Research Progress on Postoperative Minimal/Molecular Residual Disease Detection in Lung Cancer

Manqi Wu, Haifeng Shen, Ziyang Wang, Nnennaya Kanu, Kezhong Chen

Chronic Diseases and Translational Medicine · 2022

DOI: 10.1002/cdt3.10 ↗

At a glance

Übersichtsarbeit in Chronic Diseases and Translational Medicine, 2022. Written by Manqi Wu and 4 co-authors. Institution: Department of Thoracic Surgery Peking University People's Hospital, Peking University Beijing 100044 China. Cited 4 times so far (Crossref); 49 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Lung cancer is the leading cause of cancer‐related deaths worldwide. Approximately 10%–50% of patients experience relapse after radical surgery, which may be attributed to the persistence of minimal/molecular residual disease (MRD). Circulating tumor DNA (ctDNA), a common liquid biopsy approach, has been demonstrated to have significant clinical merit. In this study, we review the evidence supporting the use of ctDNA for MRD detection and discuss the potential clinical applications of postoperative MRD detection, including monitoring recurrence, guiding adjuvant treatment, and driving clinical trials in lung cancer. We will also discuss the problems that prevent the routine application of ctDNA MRD detection. Multi‐analyte methods and identification of specific genetic and molecular alterations, especially methylation, are effective detection strategies and show considerable prospects for future development. Interventional prospective studies based on ctDNA detection are needed to determine whether the application of postoperative MRD detection can improve the clinical outcomes of lung cancer patients, and the accuracy, sensitivity, specificity, and robustness of different detection methods still require optimization and refinement.

Subjects

Author keywords

circulating tumor DNAliquid biopsylung cancerminimal/molecular residual disease

Authors and institutions

  • Department of Thoracic Surgery Peking University People's Hospital, Peking University Beijing 100044 China.
  • Cancer Research UK Lung Cancer Centre of Excellence University College London Cancer Institute, University College London 72 Huntley St London WC1E 6DD UK.

Cite

APA

Wu, M., Shen, H., Wang, Z., Kanu, N., & Chen, K. (2022). Research Progress on Postoperative Minimal/Molecular Residual Disease Detection in Lung Cancer. Chronic Diseases and Translational Medicine. https://doi.org/10.1002/cdt3.10

Vancouver

Wu M, Shen H, Wang Z, Kanu N, Chen K. Research Progress on Postoperative Minimal/Molecular Residual Disease Detection in Lung Cancer. Chronic Diseases and Translational Medicine. 2022. doi:10.1002/cdt3.10

BibTeX
@article{Wu2022,
  author = {Wu, Manqi and Shen, Haifeng and Wang, Ziyang and Kanu, Nnennaya and Chen, Kezhong},
  title = {Research Progress on Postoperative Minimal/Molecular Residual Disease Detection in Lung Cancer},
  journal = {Chronic Diseases and Translational Medicine},
  year = {2022},
  doi = {10.1002/cdt3.10}
}
Start for free →